Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis
CNS Neuroscience & Therapeutics · 2023
DOI: 10.1111/cns.14302 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2023. Verfasst von Changwei Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Metabonomics & Medical NMR, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Aims
The effects of FGF21 on Parkinson's disease (PD) and its relationship with gut microbiota have not been elucidated. This study aimed to investigate whether FGF21 would attenuate behavioral impairment through microbiota–gut–brain metabolic axis in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) induced PD mice model.
Methods
Male C57BL/6 mice were rendomized into 3 groups: vehicle (CON); MPTP 30 mg/kg/day i.p. injection (MPTP); FGF21 1.5 mg/kg/d i.p. injection plus MPTP 30 mg/kg/day i.p. injection (FGF21 + MPTP). The behavioral features, metabolimics profiling, and 16 s rRNA sequencing were performed after FGF21 treatment for 7 days.
Results
MPTP‐induced PD mice showed motor and cognitive deficits accompanied by gut microbiota dysbiosis and brain‐region‐specific metabolic abnormalities. FGF21 treatment dramatically attenuated motor and cognitive dysfunction in PD mice. FGF21 produced a region‐specific alteration in the metabolic profile in the brain in ways indicative of greater ability in neurotransmitter metabolism and choline production. In addition, FGF21 also re‐structured the gut microbiota profile and increased the relative abundance of Clostridiales , Ruminococcaceae , and Lachnospiraceae , thereby rescuing the PD‐induced metabolic disorders in the colon.
Conclusion
These findings indicate that FGF21 could affect behavior and brain metabolic homeostasis in ways that promote a favorable colonic microbiota composition and through effects on the microbiota–gut–brain metabolic axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Metabonomics & Medical NMR, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
- School of Public health, Fujian Medical University, Fuzhou, China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, China.
ORCID-Profile: Hongchang Gao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
Zitieren
APA
Yang, C., Wang, W., Deng, P., Wang, X., Zhu, L., Zhao, L., Li, C., & Gao, H. (2023). Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14302
Vancouver
Yang C, Wang W, Deng P, Wang X, Zhu L, Zhao L, et al. Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis. CNS Neuroscience & Therapeutics. 2023. doi:10.1111/cns.14302
BibTeX
@article{Yang2023,
author = {Yang, Changwei and Wang, Wuqiong and Deng, Pengxi and Wang, Xinyi and Zhu, Lin and Zhao, Liangcai and Li, Chen and Gao, Hongchang},
title = {Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
doi = {10.1111/cns.14302}
}
EUVIMED